Bio-Techne Corporation ( TECH ) NASDAQ Global Select

Cena: 57.13 ( 5.8% )

Aktualizacja 08-22 21:58
NASDAQ Global Select
Branża: Biotechnology
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Bio-Techne Corporation, wraz z spółkami zależnymi, rozwija, produkuje i sprzedaje odczynniki, instrumenty i usługi na rynkach badawczych i diagnostycznych klinicznych na całym świecie. Firma działa przez dwa segmenty, nauki proteinowe oraz diagnostykę i genomikę. Segment nauk białkowych rozwija i produkuje odczynniki biologiczne stosowane w różnych aspektach badań naukowych, diagnostyki oraz terapii komórkowej i genowej, takich jak cytokiny i czynniki wzrostu, przeciwciała, małe cząsteczki, surowice hodowli tkankowej i technologie selekcji komórek. Ten segment oferuje również proteomiczne narzędzia analityczne do zautomatyzowanego przepływu pracy Western blot i multipleksowanego ELISA składa się z instrumentów ręcznych i zautomatyzowanych analizy białek i testów immunologicznych do stosowania w kwantyfikacji białek w różnych płynach biologicznych. Segment diagnostyki i genomiki opracowuje i produkuje produkty diagnostyczne, w tym kontrole, kalibratory i testy diagnostyczne dla regulowanego rynku diagnostyki, analizy diagnostycznej opartej na egzosomie, analizy diagnostycznej i genetycznej i onkologicznej opartej na tkankach; i sprzedaje produkty do badań przesiewowych genetycznych, diagnostyki onkologicznej, kontroli molekularnych i badań, a także instrumentów i produktów kontroli procesu dla hematologii, chemii i gazów krwi oraz kontroli krzepnięcia i odczynników stosowanych w różnych zastosowaniach diagnostycznych. Oferuje swoje produkty w ramach systemów badawczo -rozwojowych, Tocris Biosciences, Novus Biologicals, Proteinsimple, Advanced Cell Diagnostics, Exosome Diagnostics i Asuagen Marki. Firma była wcześniej znana jako Techne Corporation i zmieniła nazwę na Bio-Techne Corporation w listopadzie 2014 r. Bio-Techne Corporation został założony w 1976 roku i ma siedzibę w Minneapolis w stanie Minnesota.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 3 100
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 98.9715
Ilość akcji: Brak danych
Debiut giełdowy: 1989-02-09
WWW: https://www.bio-techne.com
CEO: Mr. Kim Kelderman
Adres: 614 McKinley Place N.E.
Siedziba: 55413 Minneapolis
ISIN: US09073M1045
Wskaźniki finansowe
Kapitalizacja (USD) 8 956 098 710
Aktywa: 2 736 017 000
Cena: 57.13
Wskaźnik Altman Z-Score: 13.5
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 124.2
Ilość akcji w obrocie: 99%
Średni wolumen: 2 285 651
Ilość akcji 156 767 000
Wskaźniki finansowe
Przychody TTM 1 171 582 000
Zobowiązania: 597 367 000
Przedział 52 tyg.: 46.01 - 80.95
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: 0.5
P/E branży: 28.3
Beta: 1.278
Raport okresowy: 2025-10-29
WWW: https://www.bio-techne.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Kim Kelderman Chief Executive Officer, President & Director 845 706 1968
Mr. Robert M. Gavin Vice President of Corporate Development 724 512 1968
Mr. James T. Hippel Executive Vice President of Finance & Chief Financial Officer 691 784 1971
Mr. William A. Geist President of Protein Sciences Segment 533 669 1970
Mr. Shane Bohnen Senior Vice President, General Counsel & Corporate Secretary 353 600 1975
David Clair Senior Director of Investor Relations & Corporate Development 0 0
Mr. Kevin Smyth Senior Vice President & Chief Digital Officer 0 0
Mr. Luca Cicchetti Managing Director 0 0
Dr. Gary J. Latham Ph.D. Vice President & Chief Technology Officer 0 0
Mr. Gerry Andros Vice President of Sales and Marketing 0 0
Lista ETF z ekspozycją na akcje Bio-Techne Corporation
Symbol ETF Ilość akcji Wartość
VOO 4 449 035 228 902 850
VB 3 830 875 197 098 518
RSP 2 741 451 158 209 137
VBK 2 149 693 110 601 704
IVV 1 978 059 108 259 170
SPY 1 917 831 111 055 349
XLV 1 074 377 62 092 621
IBB 999 194 54 685 880
IWR 583 602 31 940 522
GSPX.L 513 552 21 273 406
VHT 492 262 25 326 879
XDEW.DE 436 720 20 930 712
XDEW.L 436 720 23 901 692
XDWE.L 436 720 1 811 246 393
XEWG.L 436 720 18 112 463
XDEE.DE 436 720 20 930 712
SCHM 416 864 23 794 809
SXR8.DE 388 697 18 609 975
CSPX.AS 388 697 18 609 975
CSP1.L 388 697 16 101 415
CSPX.L 388 697 21 273 406
CSSPX.MI 388 697 18 609 975
IWD 363 976 19 920 395
IVE 262 978 14 392 758
IWS 245 248 13 422 422
ISPE.L 237 273 9 828 820
SPLG 231 630 13 372 834
RSPH 229 376 13 237 288
DFAS 216 694 11 859 662
VUAA.MI 212 565 9 577 066
VUAA.L 212 565 10 936 469
VUSA.AS 212 565 9 577 066
VUSD.L 212 565 10 936 469
VUSA.DE 212 565 9 577 066
VUSA.L 212 565 8 287 547
VUSA.MI 212 565 9 577 066
HEAL.L 202 937 11 106 751
DRDR.L 202 937 8 406 477
2B78.DE 202 937 9 716 185
ITOT 198 308 10 853 404
EWSP.L 179 587 7 439 237
SPYV 173 570 10 073 054
FNDA 172 899 9 854 585
SCHX 159 463 9 172 314
DFAC 146 283 8 006 068
IUSV 135 001 7 388 611
IWB 120 977 6 621 068
BBH 111 391 6 096 429
IYH 92 204 5 046 335
SCHB 91 341 5 251 436
IXJ 88 520 4 844 696
JHMM 87 917 4 738 726
SP5A.MI 86 417 4 367 225
SPYL.L 86 417 4 987 125
SPY5.PA 86 417 4 367 225
SPPE.DE 86 417 4 987 125
SPY5.DE 86 417 4 367 225
SPXE.MI 86 417 4 987 125
SPX5.L 86 417 3 779 193
SPY5.L 86 417 4 987 125
IUHE.AS 86 277 4 130 766
PRFZ 84 442 4 873 147
DGRW 83 815 4 587 194
DON 83 012 4 543 246
SCHV 80 653 4 614 462
VONV 79 169 4 073 245
QDVG.DE 75 475 3 613 594
IHCU.L 75 475 3 126 494
IUHC.L 75 475 4 130 766
BBMC 74 452 4 074 757
VWCE.DE 69 660 3 138 514
VGWL.DE 69 660 3 138 514
VWRD.L 69 660 3 584 007
VWRA.L 69 660 3 584 007
VWRP.L 69 660 2 715 924
VWRL.L 69 660 2 715 924
VWRL.AS 69 660 3 138 514
ESML 67 521 3 896 636
FHLC 67 200 3 934 560
SXRG.DE 64 314 3 079 213
CUSS.L 64 314 3 519 906
CUS1.L 64 314 2 664 146
CSUSS.MI 64 314 3 079 213
TCAF 63 215 3 459 756
IUSA.AS 59 746 2 860 514
IDUS.L 59 746 3 269 906
IUSA.DE 59 746 2 860 514
IUSA.L 59 746 2 474 926
DFUV 58 473 3 200 227
QQQJ 58 149 3 355 778
ISCG 45 778 2 505 421
JQUA 45 001 2 462 904
IWV 43 831 2 398 889
SMOT 43 533 2 382 561
SMMD 36 606 2 112 532
VOOV 36 476 1 876 690
ONEQ 35 219 2 062 072
ESGV 34 247 1 762 008
GNOM 33 367 1 826 175
SPTM 29 661 1 714 585
CE8G.DE 28 764 1 445 967
CE8.PA 28 764 1 445 967
FTQI 27 296 1 449 963
DSI 27 028 1 479 222
XSP.TO 26 790 2 135 185
DFAU 24 412 1 336 068
VONE 24 361 1 253 373
IBCF.DE 23 365 1 118 659
IUSE.L 23 365 1 118 659
IVV.AX 21 944 1 960 049
XUS.TO 20 443 1 629 275
AIVL 19 447 1 064 334
IXJ.AX 19 093 1 705 369
IQSM 16 451 900 363
VGVE.DE 16 053 723 264
VHVG.L 16 053 625 879
VDEV.L 16 053 825 926
VHVE.L 16 053 825 926
VEVE.L 16 053 625 879
VGVF.DE 16 053 723 264
SSO 15 946 872 724
DBPE.DE 15 810 757 720
XLDX.L 15 806 65 553 397
EZM 14 673 803 053
VTHR 12 215 628 461
KOMP 12 093 699 611
VNRT.DE 11 921 537 097
VNRA.L 11 921 613 335
VNRG.L 11 921 464 779
VNRA.DE 11 921 537 097
VNRT.L 11 921 464 779
VDNR.L 11 921 613 335
RSPA 11 831 682 767
SCHK 11 829 680 241
EQAL 11 181 645 255
SPXL 10 844 593 492
ZPDH.DE 10 385 524 823
SXLV.L 10 385 599 318
PTLC 9 760 534 164
XYLD 9 599 525 353
SPYI 9 266 501 661
ZPRV.DE 8 879 390 866
USSC.L 8 879 446 347
UPRO 7 763 424 868
ONEV 7 761 452 428
XHC.TO 7 700 613 706
ISCB 7 652 418 801
SPUS 7 547 413 047
RWL 7 546 435 479
XUU.TO 7 283 580 443
IYY 7 264 397 564
AVUS 7 260 418 974
SPYX 6 642 383 716
USPG.L 6 609 381 403
DTEC.L 6 559 282 535
DRUP.DE 6 559 326 578
UNIC.L 6 559 372 838
GINN 6 395 336 313
UEQD.DE 5 734 330 895
FOO.PA 5 701 286 589
DFOP.DE 5 701 286 589
LFOD.DE 5 701 286 589
GUSA 5 385 283 197
IHVV.AX 5 326 475 744
TILT 5 134 280 983
IE000Z9SJA06.SG 5 033 241 211
XDPD.DE 5 033 241 211
XDPU.L 5 033 275 449
XDPE.DE 5 033 241 211
XDPC.SW 5 033 224 276
XDPG.L 5 033 20 873 312
UBU9.DE 5 022 289 798
UC13.L 5 022 289 798
QVML 4 462 257 502
JHML 4 099 220 936
AVMC 4 073 235 052
HLAL 4 041 221 689
CURE 3 896 213 228
IGUS.L 3 714 153 844
DGRG.L 2 997 149 850
WTDM.DE 2 997 149 850
DGRP.L 2 997 149 850
DGRW.L 2 997 149 850
DGRA.L 2 997 149 850
DGRB.L 2 997 149 850
DGRE.MI 2 997 149 850
CBUG.DE 2 950 141 256
EWSA.AS 2 950 161 472
QDPL 2 866 156 856
JPME 2 814 154 010
IUSC.SW 2 718 120 869
ISPY 2 628 143 830
SZNE 2 542 139 123
GPIX 2 503 131 632
V3AL.L 2 394 123 171
V3AB.L 2 394 93 337
V3AA.L 2 394 123 171
GVUS 2 014 105 916
GGRB.L 1 983 99 150
GGRW.L 1 983 99 150
WTEM.DE 1 983 99 150
GGRG.L 1 983 99 150
GGRE.MI 1 983 99 150
GGRP.L 1 983 99 150
GGRA.L 1 983 99 150
XWD.TO 1 940 154 621
DCOR 1 826 99 936
DFSU 1 752 95 886
DTD 1 746 95 558
RXL 1 653 90 468
MMSC 1 489 79 095
XVV 1 396 80 563
FNDB 1 344 77 048
AVLC 1 215 70 117
R1VL.L 1 171 64 115
HCMT 1 167 63 869
XBAL.TO 1 085 86 501
WDNA.L 1 078 53 900
WBIO.L 1 078 53 900
XUH.TO 1 075 62 045
BMED 964 52 746
SPXT 920 50 351
USFM.L 882 50 882
USUE.DE 882 50 882
STXM 853 46 684
PBP 836 48 245
AVSU 753 43 455
VLU 688 39 927
MID 680 195 285
WDNA 524 28 678
SPUU 491 26 872
STXG 407 22 275
BUYO 379 20 743
QQJG 379 21 872
HELX 241 13 908
ONEO 201 11 656
SPXE 200 10 946
SPXN 198 10 836
PHDG 181 10 445
XYLG 140 7 662
XRMI 77 4 214
XTR.TO 44 2 511
MMTM 20 1 152
XCLR 11 602
XTR 7 383
IGDA.L 0 169 304
P500.DE 0 7 697 838
FWRG.L 0 8 152 579
SPXD.L 0 8 785 480
SPXS.L 0 8 785 480
EQL.TO 0 3 052 147
IE00BN4Q0370.SG 0 0
XLVS.L 0 652 273
G500.L 0 663 881 786
D500.DE 0 7 697 838
EQQJ.L 0 176 113
SPES.L 0 177 978 643
SPEX.L 0 177 978 643
IE00BYML9W36.SG 0 7 697 838
SPXP.L 0 667 336 325
SPEQ.L 0 2 343 088
SPXD.SW 0 8 785 480
PZW.TO 0 22 839
EQJS.L 0 13 377 399
XLVP.L 0 49 546 008
E500.DE 0 7 675 925
SPXS.MI 0 7 697 838
IE00B3YCGJ38.SG 0 7 697 838
FTWD.DE 0 94 041
SPED.L 0 2 343 088
DWSH -2 070 -113 291
Wiadomości dla Bio-Techne Corporation
Tytuł Treść Źródło Aktualizacja Link
BMRN or TECH: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now? zacks.com 2025-01-02 14:46:39 Czytaj oryginał (ang.)
ALPHA PRO TECH, LTD. ANNOUNCES $2 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM NOGALES, Ariz., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced that its Board of Directors has authorized a $2.0 million expansion of the Company's existing share repurchase program. globenewswire.com 2024-12-23 18:00:00 Czytaj oryginał (ang.)
Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain? TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic characterization and development processes. zacks.com 2024-12-23 11:05:23 Czytaj oryginał (ang.)
BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE MINNEAPOLIS , Dec. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m. prnewswire.com 2024-12-20 09:00:00 Czytaj oryginał (ang.)
YSX TECH. CO., LTD Announces Closing of Its Initial Public Offering and Full Exercise of Underwriter's Over-Allotment Option Guangzhou, Dec. 19, 2024 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 Class A ordinary shares (the “Ordinary Shares”) at a public offering price of $4.00 per share for total gross proceeds of approximately $5,000,000, before deducting underwriting discounts and other offering expenses. The Offering closed on December 19, 2024(the “Closing Date”), and the Ordinary Shares commenced trading on Nasdaq Capital Market on December 18, 2024, under the ticker symbol “YSXT”. globenewswire.com 2024-12-19 14:10:00 Czytaj oryginał (ang.)
BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT MINNEAPOLIS , Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex™ System) and liquid chromatography mass spectrometry (BioAccord™ LC-MS System from Waters) to deliver innovative solutions that optimize workflows, improve precision, and accelerate development timelines. prnewswire.com 2024-12-19 09:00:00 Czytaj oryginał (ang.)
ScaleReady awards a G-Rex® Grant to Moonlight Bio ST. PAUL, Minn. , Dec. 18, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. prnewswire.com 2024-12-18 09:00:00 Czytaj oryginał (ang.)
YSX TECH. CO., LTD Announces Pricing of Its Initial Public Offering Guangzhou, Dec. 17, 2024 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 Class A ordinary shares (the “Ordinary Shares”) at a public offering price of $4.00 per share for total gross proceeds of approximately $5,000,000, before deducting underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on December 18, 2024, under the ticker symbol “YSXT”. globenewswire.com 2024-12-17 19:18:00 Czytaj oryginał (ang.)
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain? TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay. zacks.com 2024-12-12 10:16:10 Czytaj oryginał (ang.)
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY MINNEAPOLIS , Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics (ACD), and Asuragen brands across Turkey. prnewswire.com 2024-12-12 09:00:00 Czytaj oryginał (ang.)
BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium MINNEAPOLIS , Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. prnewswire.com 2024-12-10 09:00:00 Czytaj oryginał (ang.)
Should You Continue to Retain Bio-Techne Stock in Your Portfolio? Bio-Techne's success with four growth verticals and expansion through acquisitions bode well. zacks.com 2024-12-02 09:11:09 Czytaj oryginał (ang.)
Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue? Techne (TECH) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-11-29 14:36:25 Czytaj oryginał (ang.)
BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE MINNEAPOLIS , Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. prnewswire.com 2024-11-27 09:00:00 Czytaj oryginał (ang.)
Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne WEST SACRAMENTO, Calif. , Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ: TECH). prnewswire.com 2024-11-25 11:02:00 Czytaj oryginał (ang.)
OverT Bio Receives $120K G-Rex® Grant to Propel Solid Tumor Cell Therapy Advancements NEW YORK--(BUSINESS WIRE)--OverT Bio, an NYC-based cell therapy company, today announced that it has been awarded a $120,000 G-Rex Grant from ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM. This grant will support OverT Bio's ongoing development efforts that will lead to next generation cell therapies for solid tumors, based on innovative data-driven discovery platforms OverTargetTM and OverTCRTM. The G-Rex Grant is part of. businesswire.com 2024-11-22 11:00:00 Czytaj oryginał (ang.)
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES MINNEAPOLIS , Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates. prnewswire.com 2024-11-20 09:00:00 Czytaj oryginał (ang.)
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH MINNEAPOLIS , Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. prnewswire.com 2024-11-18 09:00:00 Czytaj oryginał (ang.)
BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS , Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811. prnewswire.com 2024-11-14 09:00:00 Czytaj oryginał (ang.)
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation This press release updates the IVDR Classification to Class B from the prior Class C.  MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. prnewswire.com 2024-11-11 19:47:00 Czytaj oryginał (ang.)